This is a single-center clinical trial of 20 COVID-19 patients aged 30 to 79 years being treated with 5 sessions of hyperbaric oxygen therapy at 2.0 ATA (90 minutes) at NYU Winthrop Hospital from March 31 to April 28, 2020. “The results demonstrated the safety of hyperbaric oxygen among COVID-19 patients and strongly suggests the need for a well-designed, multi-center randomized control trial” <view study> Read Less

Promising clinical studies have emerged suggesting HBOT's efficacy for reducing postoperative complications. This RCT (randomized controlled trials) review of literature supports the use of hyperbaric oxygen therapy peri-operatively, and gives value for this procedure to be a “promising intervention to improve surgical patient outcome”. <view study> Read Less

Adipose-derived stem cells are considered as candidate cells for regenerative plastic surgery. “Hyperbaric oxygen therapy with 3 ATA increases viability and proliferation of adipose-derived stem cells, alters marker expression and subpopulations, decreases TGF-β secretion, and skews adipose-derived stem cells toward adipogenic differentiation” <view study> Read Less

The majority of MS patients using hyperbaric oxygen do so at 1.5 ATA for 60 minutes. A laboratory-based replication of this treatment regimen (and the common MS protocols) gives a better understanding of the physiological effects of hyperbaric oxygen treatment on brain cells and their role in neuro-inflammation. <view study> Read Less

This was a laboratory-based “in vitro” study which showed that hyperbaric exposure was able to suppress HIV-1 replication. “The exposure to hyperbaric oxygen at the pressure of 2.4 ATA and 98% oxygen was able to produce ROS and RNS molecules, which play a role in cellular adaptive responses through increasing the expression of nfĸb, p21 and mRNA of interferon α2 plays a role in inhibition mechanism of HIV-1 replication in cells.” <view study> Read Less